Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where John C. Reid is active.

Publication


Featured researches published by John C. Reid.


Journal of Virology | 2010

Structural basis for the inhibition of RNase H activity of HIV-1 reverse transcriptase by RNase H active site-directed inhibitors.

Hua-Poo Su; Youwei Yan; G. Sridhar Prasad; Robert F. Smith; Christopher L. Daniels; Pravien Abeywickrema; John C. Reid; H. Marie Loughran; Maria Kornienko; Sujata Sharma; Jay A. Grobler; Bei Xu; Vinod V. Sardana; Timothy J. Allison; Peter D. Williams; Paul L. Darke; Daria J. Hazuda; Sanjeev Munshi

ABSTRACT HIV/AIDS continues to be a menace to public health. Several drugs currently on the market have successfully improved the ability to manage the viral burden in infected patients. However, new drugs are needed to combat the rapid emergence of mutated forms of the virus that are resistant to existing therapies. Currently, approved drugs target three of the four major enzyme activities encoded by the virus that are critical to the HIV life cycle. Although a number of inhibitors of HIV RNase H activity have been reported, few inhibit by directly engaging the RNase H active site. Here, we describe structures of naphthyridinone-containing inhibitors bound to the RNase H active site. This class of compounds binds to the active site via two metal ions that are coordinated by catalytic site residues, D443, E478, D498, and D549. The directionality of the naphthyridinone pharmacophore is restricted by the ordering of D549 and H539 in the RNase H domain. In addition, one of the naphthyridinone-based compounds was found to bind at a second site close to the polymerase active site and non-nucleoside/nucleotide inhibitor sites in a metal-independent manner. Further characterization, using fluorescence-based thermal denaturation and a crystal structure of the isolated RNase H domain reveals that this compound can also bind the RNase H site and retains the metal-dependent binding mode of this class of molecules. These structures provide a means for structurally guided design of novel RNase H inhibitors.


Journal of the American Chemical Society | 2012

Mechanism of Action of the Cell-Division Inhibitor PC190723: Modulation of FtsZ Assembly Cooperativity

Nathaniel L. Elsen; Jun Lu; Gopal Parthasarathy; John C. Reid; Sujata Sharma; Stephen M. Soisson; Kevin J. Lumb

The cooperative assembly of FtsZ, the prokaryotic homologue of tubulin, plays an essential role in cell division. FtsZ is a potential drug target, as illustrated by the small-molecule cell-cycle inhibitor and antibacterial agent PC190723 that targets FtsZ. We demonstrate that PC190723 negatively modulates Staphylococcus aureus FtsZ polymerization cooperativity as reflected in polymerization at lower concentrations without a defined critical concentration. The crystal structure of the S. aureus FtsZ-PC190723 complex shows a domain movement that would stabilize the FtsZ protofilament over the monomeric state, with the conformational change mediated from the GTP-binding site to the C-terminal domain via helix 7. Together, the results reveal the molecular mechanism of FtsZ modulation by PC190723 and a conformational switch to the high-affinity state that enables polymer assembly.


BMC Structural Biology | 2010

Structural definition and substrate specificity of the S28 protease family: the crystal structure of human prolylcarboxypeptidase

Stephen Soisson; Sangita Patel; Pravien Abeywickrema; Noel Byrne; Ronald E. Diehl; Dawn L. Hall; Rachael E. Ford; John C. Reid; Keith Rickert; Jennifer M. Shipman; Sujata Sharma; Kevin J. Lumb

BackgroundThe unique S28 family of proteases is comprised of the carboxypeptidase PRCP and the aminopeptidase DPP7. The structural basis of the different substrate specificities of the two enzymes is not understood nor has the structure of the S28 fold been described.ResultsThe experimentally phased 2.8 Å crystal structure is presented for human PRCP. PRCP contains an α/β hydrolase domain harboring the catalytic Asp-His-Ser triad and a novel helical structural domain that caps the active site. Structural comparisons with prolylendopeptidase and DPP4 identify the S1 proline binding site of PRCP. A structure-based alignment with the previously undescribed structure of DPP7 illuminates the mechanism of orthogonal substrate specificity of PRCP and DPP7. PRCP has an extended active-site cleft that can accommodate proline substrates with multiple N-terminal residues. In contrast, the substrate binding groove of DPP7 is occluded by a short amino-acid insertion unique to DPP7 that creates a truncated active site selective for dipeptidyl proteolysis of N-terminal substrates.ConclusionThe results define the structure of the S28 family of proteases, provide the structural basis of PRCP and DPP7 substrate specificity and enable the rational design of selective PRCP modulators.


Protein Science | 2007

Crystal structures of the N‐terminal kinase domain of human RSK1 bound to three different ligands: Implications for the design of RSK1 specific inhibitors

Mari Ikuta; Maria Kornienko; Noel Byrne; John C. Reid; Hidehito Kotani; Sanjeev Munshi

The p90 ribosomal S6 kinases (RSKs) also known as MAPKAP‐Ks are serine/threonine protein kinases that are activated by ERK or PDK1 and act as downstream effectors of mitogen‐activated protein kinase (MAPK). RSK1, a member of the RSK family, contains two distinct kinase domains in a single polypeptide chain, the regulatory C‐terminal kinase domain (CTKD) and the catalytic N‐terminal kinase domain (NTKD). Autophosphorylation of the CTKD leads to activation of the NTKD that subsequently phosphorylates downstream substrates. Here we report the crystal structures of the unactivated RSK1 NTKD bound to different ligands at 2.0 Å resolution. The activation loop and helix αC, key regulatory elements of kinase function, are disordered. The DFG motif of the inactive RSK1 adopts an “active‐like” conformation. The β‐PO4 group in the AMP–PCP complex adopts a unique conformation that may contribute to inactivity of the enzyme. Structures of RSK1 ligand complexes offer insights into the design of novel anticancer agents and into the regulation of the catalytic activity of RSKs.


Journal of Biological Chemistry | 2011

Structural Basis for Selective Small Molecule Kinase Inhibition of Activated c-Met

Keith Rickert; Sangita B. Patel; Timothy J. Allison; Noel Byrne; Paul L. Darke; Rachael E. Ford; David J. Guerin; Dawn L. Hall; Maria Kornienko; Jun Lu; Sanjeev Munshi; John C. Reid; Jennifer M. Shipman; Elizabeth Stanton; Kevin J. Wilson; Jonathon R. Young; Stephen M. Soisson; Kevin J. Lumb

The receptor tyrosine kinase c-Met is implicated in oncogenesis and is the target for several small molecule and biologic agents in clinical trials for the treatment of cancer. Binding of the hepatocyte growth factor to the cell surface receptor of c-Met induces activation via autophosphorylation of the kinase domain. Here we describe the structural basis of c-Met activation upon autophosphorylation and the selective small molecule inhibiton of autophosphorylated c-Met. MK-2461 is a potent c-Met inhibitor that is selective for the phosphorylated state of the enzyme. Compound 1 is an MK-2461 analog with a 20-fold enthalpy-driven preference for the autophosphorylated over unphosphorylated c-Met kinase domain. The crystal structure of the unbound kinase domain phosphorylated at Tyr-1234 and Tyr-1235 shows that activation loop phosphorylation leads to the ejection and disorder of the activation loop and rearrangement of helix αC and the G loop to generate a viable active site. Helix αC adopts a orientation different from that seen in activation loop mutants. The crystal structure of the complex formed by the autophosphorylated c-Met kinase domain and compound 1 reveals a significant induced fit conformational change of the G loop and ordering of the activation loop, explaining the selectivity of compound 1 for the autophosphorylated state. The results highlight the role of structural plasticity within the kinase domain in imparting the specificity of ligand binding and provide the framework for structure-guided design of activated c-Met inhibitors.


Journal of Biological Chemistry | 2008

Structure of human prostasin, a target for the regulation of hypertension

Keith Rickert; Paul Kelley; Noel Byrne; Ronald E. Diehl; Dawn L. Hall; Allison Montalvo; John C. Reid; Jennifer M. Shipman; Bradley W. Thomas; Sanjeev Munshi; Paul L. Darke; Hua-Poo Su

Prostasin (also called channel activating protease-1 (CAP1)) is an extracellular serine protease implicated in the modulation of fluid and electrolyte regulation via proteolysis of the epithelial sodium channel. Several disease states, particularly hypertension, can be affected by modulation of epithelial sodium channel activity. Thus, understanding the biochemical function of prostasin and developing specific agents to inhibit its activity could have a significant impact on a widespread disease. We report the expression of the prostasin proenzyme in Escherichia coli as insoluble inclusion bodies, refolding and activating via proteolytic removal of the N-terminal propeptide. The refolded and activated enzyme was shown to be pure and monomeric, with kinetic characteristics very similar to prostasin expressed from eukaryotic systems. Active prostasin was crystallized, and the structure was determined to 1.45Å resolution. These apoprotein crystals were soaked with nafamostat, allowing the structure of the inhibited acyl-enzyme intermediate structure to be determined to 2.0Å resolution. Comparison of the inhibited and apoprotein forms of prostasin suggest a mechanism of regulation through stabilization of a loop which interferes with substrate recognition.


Acta Crystallographica Section F-structural Biology and Crystallization Communications | 2010

Expression, purification and crystallization of human prolylcarboxypeptidase.

Pravien Abeywickrema; Sangita Patel; Noel Byrne; Ronald E. Diehl; Dawn L. Hall; Rachael E. Ford; Keith Rickert; John C. Reid; Jennifer M. Shipman; Wayne M. Geissler; Kelly Ann D. Pryor; Ranabir SinhaRoy; Stephen Soisson; Kevin J. Lumb; Sujata Sharma

Prolylcarboxypeptidase (PrCP) is a lysosomal serine carboxypeptidase that cleaves a variety of C-terminal amino acids adjacent to proline and has been implicated in diseases such as hypertension and obesity. Here, the robust production, purification and crystallization of glycosylated human PrCP from stably transformed CHO cells is described. Purified PrCP yielded crystals belonging to space group R32, with unit-cell parameters a = b = 181.14, c = 240.13 A, that diffracted to better than 2.8 A resolution.


Journal of Biological Chemistry | 2013

Structure of the Bacterial Deacetylase LpxC Bound to the Nucleotide Reaction Product Reveals Mechanisms of Oxyanion Stabilization and Proton Transfer

Gina M. Clayton; Daniel Klein; Keith W. Rickert; Sangita B. Patel; Maria Kornienko; Joan Zugay-Murphy; John C. Reid; Srivanya Tummala; Sujata Sharma; Sheo B. Singh; Lynn Miesel; Kevin J. Lumb; Stephen M. Soisson

Background: LpxC is a metal-dependent deacetylase essential for lipopolysaccharide biosynthesis. Results: The LpxC reaction product binds an extensive, conserved groove with the 2-amino group positioned in the active site. Conclusion: The product-bound LpxC structure reveals conserved ligand interactions and stabilization of a phosphate mimic of the oxyanion intermediate. Significance: LpxC structures are critical to elucidate the catalytic mechanism and design of novel antibiotics. The emergence of antibiotic-resistant strains of pathogenic bacteria is an increasing threat to global health that underscores an urgent need for an expanded antibacterial armamentarium. Gram-negative bacteria, such as Escherichia coli, have become increasingly important clinical pathogens with limited treatment options. This is due in part to their lipopolysaccharide (LPS) outer membrane components, which dually serve as endotoxins while also protecting Gram-negative bacteria from antibiotic entry. The LpxC enzyme catalyzes the committed step of LPS biosynthesis, making LpxC a promising target for new antibacterials. Here, we present the first structure of an LpxC enzyme in complex with the deacetylation reaction product, UDP-(3-O-(R-3-hydroxymyristoyl))-glucosamine. These studies provide valuable insight into recognition of substrates and products by LpxC and a platform for structure-guided drug discovery of broad spectrum Gram-negative antibiotics.


Nature Chemical Biology | 2017

Insights into activity and inhibition from the crystal structure of human O-GlcNAcase

Nathaniel L. Elsen; Sangita B. Patel; Rachael E. Ford; Dawn L. Hall; Fred Hess; Hari Kandula; Maria Kornienko; John C. Reid; Harold G. Selnick; Jennifer M. Shipman; Sujata Sharma; Kevin J. Lumb; Stephen M. Soisson; Daniel Klein

O-GlcNAc hydrolase (OGA) catalyzes removal of βα-linked N-acetyl-D-glucosamine from serine and threonine residues. We report crystal structures of Homo sapiens OGA catalytic domain in apo and inhibited states, revealing a flexible dimer that displays three unique conformations and is characterized by subdomain α-helix swapping. These results identify new structural features of the substrate-binding groove adjacent to the catalytic site and open new opportunities for structural, mechanistic and drug discovery activities.


Journal of Biological Chemistry | 2015

Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4

Samantha J. Allen; Gopal Parthasarathy; Paul L. Darke; Ronald E. Diehl; Rachael E. Ford; Dawn L. Hall; Scott A. Johnson; John C. Reid; Keith W. Rickert; Jennifer M. Shipman; Stephen Soisson; Paul Zuck; Sanjeev K. Munshi; Kevin J. Lumb

Background: GRK4 mediates GPCR phosphorylation and is implicated in hypertension. Results: The crystal structure of human GRK4α A486V is presented. Phosphorylation assays highlight kinetic differences between wild-type GRK4α and GRK4α A486V. Conclusion: GRK4α has unusual features that help explain the effects of GRK4 mutations and GRK4 biology. Significance: This work provides a structural basis for GRK4 function. G-protein-coupled receptor (GPCR) kinases (GRKs) bind to and phosphorylate GPCRs, initiating the process of GPCR desensitization and internalization. GRK4 is implicated in the regulation of blood pressure, and three GRK4 polymorphisms (R65L, A142V, and A486V) are associated with hypertension. Here, we describe the 2.6 Å structure of human GRK4α A486V crystallized in the presence of 5′-adenylyl β,γ-imidodiphosphate. The structure of GRK4α is similar to other GRKs, although slight differences exist within the RGS homology (RH) bundle subdomain, substrate-binding site, and kinase C-tail. The RH bundle subdomain and kinase C-terminal lobe form a strikingly acidic surface, whereas the kinase N-terminal lobe and RH terminal subdomain surfaces are much more basic. In this respect, GRK4α is more similar to GRK2 than GRK6. A fully ordered kinase C-tail reveals interactions linking the C-tail with important determinants of kinase activity, including the αB helix, αD helix, and the P-loop. Autophosphorylation of wild-type GRK4α is required for full kinase activity, as indicated by a lag in phosphorylation of a peptide from the dopamine D1 receptor without ATP preincubation. In contrast, this lag is not observed in GRK4α A486V. Phosphopeptide mapping by mass spectrometry indicates an increased rate of autophosphorylation of a number of residues in GRK4α A486V relative to wild-type GRK4α, including Ser-485 in the kinase C-tail.

Collaboration


Dive into the John C. Reid's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Maria Kornienko

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Keith Rickert

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Noel Byrne

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Paul L. Darke

United States Military Academy

View shared research outputs
Top Co-Authors

Avatar

Hua-Poo Su

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar

Kevin J. Lumb

Colorado State University

View shared research outputs
Researchain Logo
Decentralizing Knowledge